Utility of contrast-enhanced harmonic endoscopic ultrasonography for predicting the prognosis of pancreatic neuroendocrine neoplasms.
contrast-enhanced harmonic endoscopic ultrasonography
endoscopic ultrasonography
pancreatic neuroendocrine tumor
sonazoid
Journal
Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
ISSN: 1443-1661
Titre abrégé: Dig Endosc
Pays: Australia
ID NLM: 9101419
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
20
04
2020
accepted:
28
09
2020
pubmed:
7
10
2020
medline:
29
7
2021
entrez:
6
10
2020
Statut:
ppublish
Résumé
Pancreatic neuroendocrine neoplasms (PanNENs), including Grade 1 (G1) or G2 tumors, can have a poor prognosis. This study investigated the value of contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) for predicting the prognosis of PanNENs. This single-center, retrospective study included 47 consecutive patients who underwent CH-EUS and were diagnosed with PanNEN by surgical resection or EUS-guided fine needle aspiration between December 2011 and February 2016. Patients were divided into aggressive and non-aggressive groups according to the degree of clinical malignancy. CH-EUS was assessed regarding its capacity for diagnosing aggressive PanNEN, the correspondence between contrast patterns and pathological features, and its ability to predict the prognosis of PanNEN. There were 19 cases of aggressive PanNEN and 28 cases of non-aggressive PanNEN. The aggressive group included three G1, four G2, three G3 tumors, three mixed neuroendocrine non-neuroendocrine neoplasms, and six neuroendocrine carcinomas. CH-EUS was superior to contrast-enhanced computed tomography for the diagnosis of aggressive PanNEN (P < 0.001): hypo-enhancement on CH-EUS was an indicator of aggressive PanNEN, with sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 94.7%, 100%, 100%, 96.6%, and 97.9%, respectively. Among G1/G2 PanNENs, cases with hypo-enhancement on CH-EUS had a poorer prognosis than those with hyper/iso-enhancement (P = 0.0009). Assessment of 36 resected specimens showed that hypo-enhancement on CH-EUS was associated with smaller and fewer vessels and greater degree of fibrosis. Contrast-enhanced harmonic endoscopic ultrasonography may be useful for predicting the prognosis of PanNENs.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Pancreatic neuroendocrine neoplasms (PanNENs), including Grade 1 (G1) or G2 tumors, can have a poor prognosis. This study investigated the value of contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) for predicting the prognosis of PanNENs.
METHODS
METHODS
This single-center, retrospective study included 47 consecutive patients who underwent CH-EUS and were diagnosed with PanNEN by surgical resection or EUS-guided fine needle aspiration between December 2011 and February 2016. Patients were divided into aggressive and non-aggressive groups according to the degree of clinical malignancy. CH-EUS was assessed regarding its capacity for diagnosing aggressive PanNEN, the correspondence between contrast patterns and pathological features, and its ability to predict the prognosis of PanNEN.
RESULTS
RESULTS
There were 19 cases of aggressive PanNEN and 28 cases of non-aggressive PanNEN. The aggressive group included three G1, four G2, three G3 tumors, three mixed neuroendocrine non-neuroendocrine neoplasms, and six neuroendocrine carcinomas. CH-EUS was superior to contrast-enhanced computed tomography for the diagnosis of aggressive PanNEN (P < 0.001): hypo-enhancement on CH-EUS was an indicator of aggressive PanNEN, with sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 94.7%, 100%, 100%, 96.6%, and 97.9%, respectively. Among G1/G2 PanNENs, cases with hypo-enhancement on CH-EUS had a poorer prognosis than those with hyper/iso-enhancement (P = 0.0009). Assessment of 36 resected specimens showed that hypo-enhancement on CH-EUS was associated with smaller and fewer vessels and greater degree of fibrosis.
CONCLUSION
CONCLUSIONS
Contrast-enhanced harmonic endoscopic ultrasonography may be useful for predicting the prognosis of PanNENs.
Substances chimiques
Contrast Media
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
829-839Informations de copyright
© 2020 Japan Gastroenterological Endoscopy Society.
Références
Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011; 40: 1-18.
Yao JC, Hassan M, Phan A et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-72.
Zhou J, Enewold L, Stojadinovic A et al. Incidence rates of exocrine and endocrine pancreatic cancers in the United States. Cancer Causes Control 2010; 21: 853-61.
Lee DW, Kim MK, Kim HG. Diagnosis of pancreatic neuroendocrine tumors. Clin Endosc 2017; 50: 537-45.
Sundin A. Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol 2012; 26: 803-18.
Herwick S, Miller FH, Keppke AL. MRI of islet cell tumors of the pancreas. AJR Am J Roentgenol 2006; 187: W472-W480.
Sundin A, Vullierme MP, Kaltsas G, Plöckinger U; Mallorca Consensus Conference Participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009; 90: 167-83.
Kitano M, Kudo M, Yamao K et al. Characterization of small solid tumors in the pancreas: the value of contrast-enhanced harmonic endoscopic ultrasonography. Am J Gastroenterol 2012; 107: 303-10.
Omoto S, Takenaka M, Kitano M et al. Characterization of pancreatic tumors with quantitative perfusion analysis in contrast-enhanced harmonic endoscopic ultrasonography. Oncology 2017; 93: 55-60.
Yamashita Y, Shimokawa T, Napoléon B et al. Value of contrast-enhanced harmonic endoscopic ultrasonography with enhancement pattern for diagnosis of pancreatic cancer: a meta-analysis. Dig Endosc 2019; 31: 125-33.
Rosai J, Osamura RY, Klöppel G, Lloyd RV (Eds) WHO Classification of Tumours of Endocrine Organs, 4th edn. Lyon, France: IARC Press, 2017.
Hasegawa T, Yamao K, Hijioka S et al. Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors. Endoscopy 2014; 46: 32-8.
Hwang HS, Kim Y, An S et al. Grading by the Ki-67 labeling index of endoscopic ultrasound-guided fine needle aspiration biopsy specimens of pancreatic neuroendocrine tumors can be underestimated. Pancreas 2018; 47: 1296-303.
Grosse C, Noack P, Silye R. Accuracy of grading pancreatic neuroendocrine neoplasms with Ki-67 index in fine-needle aspiration cellblock material. Cytopathology 2019; 30: 187-93.
Di Leo M, Poliani L, Rahal D et al. Pancreatic neuroendocrine tumors: the role of endoscopic ultrasound biopsy in diagnosis and grading based on the WHO 2017 classification. Dig Dis 2019; 37: 325-33.
Witt BL, Factor RE, Chadwick BE, Caron J, Siddiqui AA, Adler DG. Evaluation of the SharkCore® needle for EUS-guided core biopsy of pancreatic neuroendocrine tumors. Endosc Ultrasound 2018; 7: 323-8.
Rinke A, Müller HH, Schade-Brittinger C et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-63.
Palazzo M, Napoléon B, Gincul R et al. Contrast harmonic EUS for the prediction of pancreatic neuroendocrine tumor aggressiveness (with videos). Gastrointest Endosc 2018; 87: 1481-8.
Awai K, Hiraishi K, Hori S. Effect of contrast material injection duration and rate on aortic peak time and peak enhancement at dynamic CT involving injection protocol with dose tailored to patient weight. Radiology 2004; 230: 142-50.
Jeon SK, Lee JM, Joo I et al. Nonhypervascular pancreatic neuroendocrine tumors: differential diagnosis from pancreatic ductal adenocarcinomas at MR Imaging-Retrospective Cross-Sectional Study. Radiology 2017; 284: 77-87.
Fukukura Y, Kumagae Y, Higashi R et al. Extracellular volume fraction determined by equilibrium contrast-enhanced multidetector computed tomography as a prognostic factor in unresectable pancreatic adenocarcinoma treated with chemotherapy. Eur Radiol 2019; 29: 353-61.
Kamata K, Watanabe T, Minaga K et al. Intestinal dysbiosis mediates experimental autoimmune pancreatitis via activation of plasmacytoid dendritic cells. Int Immunol 2019; 31: 795-809.
Nanno Y, Toyama H, Otani K et al. Microscopic venous invasion in patients with pancreatic neuroendocrine tumor as a potential predictor postoperative recurrence. Pancreatology 2016; 16: 882-7.
Blakely AM, Lafaro KJ, Li D et al. Lymphovascular invasion predicts lymph node involvement in small pancreatic neuroendocrine tumors. Neuroendocrinology 2020; 110: 384-92.
Lee LC, Grant CS, Salomao DR et al. Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management. Surgery 2012; 152: 965-74.
Gaujoux S, Partelli S, Maire F et al. Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab 2013; 98: 4784-9.
Jung JG, Lee KT, Woo YS et al. Behavior of small, asymptomatic, nonfunctioning pancreatic neuroendocrine tumors (NF-PNETs). Medicine 2015; 94: e983.
Rosenberg AM, Friedmann P, Del Rivero J, Libutti SK, Laird AM. Resection versus expectant management of small incidentally discovered nonfunctional pancreatic neuroendocrine tumors. Surgery 2016; 159: 302-9.
Choi JH, Choi YH, Kang J et al. Natural history of small pancreatic lesions suspected to be nonfunctioning pancreatic neuroendocrine tumors. Pancreas 2018; 47: 1357-63.
Haynes AB, Deshpande V, Ingkakul T et al. Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes. Arch Surg 2011; 146: 534-8.
Ricci C, Casadei R, Taffurelli G et al. Sporadic small (≤20 mm) nonfunctioning pancreatic neuroendocrine neoplasm: is the risk of malignancy negligible when adopting a more conservative strategy? A Systematic Review and Meta-Analysis. Ann Surg Oncol 2017; 24: 2603-10.
Takada S, Kato H, Saragai Y et al. Contrast-enhanced harmonic endoscopic ultrasound using time-intensity curve analysis predicts pathological grade of pancreatic neuroendocrine neoplasm. J Med Ultrason (2001) 2019; 46: 449-58.
Poultsides GA, Huang LC, Chen Y et al. Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis. Ann Surg Oncol 2012; 19: 2295-303.
Kawamoto S, Johnson PT, Shi C et al. Pancreatic neuroendocrine tumor with cystlike changes: evaluation with MDCT. AJR Am J Roentgenol 2013; 200: W283-290.
Katsuta E, Kudo A, Akashi T et al. Macroscopic morphology for estimation of malignant potential in pancreatic neuroendocrine neoplasm. J Cancer Res Clin Oncol 2016; 142: 1299-306.
Marion-Audibert AM, Barel C, Gouysse G et al. Low microvessel density is an unfavourable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology 2003; 125: 1094-104.
Couvelard A, O’Toole D, Turley H et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 2005; 92: 94-101.
Tonino P, Abreu C. Microvessel density is associated with VEGF and α-SMA expression in different regions of human gastrointestinal carcinomas. Cancers (Basel) 2011; 3: 3405-18.
Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309.
Tanaka K, Hayashi T, Utsunomiya R et al. Endoscopic ultrasound-guided fine needle aspiration for diagnosing pancreatic mass in patients with surgically altered upper gastrointestinal anatomy. Dig Endosc 2020; 32: 967-73.
Yane K, Kuwatani M, Yoshida M et al. Non-negligible rate of needle tract seeding after endoscopic ultrasound-guided fine-needle aspiration for patients undergoing distal pancreatectomy for pancreatic cancer. Dig Endosc 2020; 32: 801-11.
Yoshinaga S, Itoi T, Yamao K et al. Safety and efficacy of endoscopic ultrasound-guided fine needle aspiration for pancreatic masses: a prospective multicenter study. Dig Endosc 2020; 32: 114-26.
Bang JY, Kirtane S, Krall K et al. In memoriam: fine-needle aspiration, birth: Fine-needle biopsy: the changing trend in endoscopic ultrasound-guided tissue acquisition. Dig Endosc 2019; 31: 197-202.